QQ客服 官方微博 反馈留言

浏览/检索结果: 共16条，第1-10条 帮助 限定条件 发表日期：2018    专题：山东大学    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review. 期刊论文 Clinical and translational medicine, 2018, 卷号: 7, 期号: 1 作者:  Liu, Zhichao;  Bao, Youting;  Li, Butuo;  Sun, Xindong;  Wang, Linlin 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/11 Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer 期刊论文 CANCER LETTERS, 2018, 卷号: 421, 页码: 59-62 作者:  Zhang, Yun;  Lin, Qin;  Xu, Ting;  Deng, Weiye;  Yu, Jinming 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/11 Non-small cell lung cancer  Radiotherapy  Targeted therapies  immunotherapies   A Randomized, Double-Blind, Placebo-Controlled Trial of Chemotherapy Combined with Yangzheng Xiaoji in Advanced NSCLC 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2018, 卷号: 13, 期号: 10, 页码: S359-S360 作者:  Xing, L.;  Wang, J.;  Li, L.;  Ma, Z.;  Hu, C. 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/11 Yangzheng Xiaoji (YZXJ)  chemotherapy  Advanced Non-Small Cell Lung  Cancer   First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice? 期刊论文 CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 卷号: 81, 期号: 3, 页码: 443-453 作者:  Wang, Shuyun;  Gao, Aiqin;  Liu, Jie;  Sun, Yuping 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/11 Activating EGFR mutation  NSCLC  EGFR-TKIs  Cytotoxic chemotherapy  First-line treatment   Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer 期刊论文 LUNG CANCER, 2018, 卷号: 122, 页码: 32-37 作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/11 Anlotinib  Non-small cell lung cancer  Quality of life   Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer 期刊论文 INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2, 页码: 315-322 作者:  Ouyang, Xuenong;  Shi, Meiqi;  Jie, Fangwei;  Bai, Yuxian;  Shen, Peng 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/11 Phase III  Dulanermin  NSCLC  Progression-free survival  Objective  response rate   Integrated texture parameter of F-18-FDG PET may be a stratification factor for the survival of nonoperative patients with locally advanced non-small-cell lung cancer 期刊论文 NUCLEAR MEDICINE COMMUNICATIONS, 2018, 卷号: 39, 期号: 8, 页码: 732-740 作者:  Liu, Wenju;  Sun, Xiaorong;  Qi, Yiqiang;  Jia, Xiufen;  Huang, Yong 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/11 non-small-cell lung cancer  positron-emission tomography  prognosis  radiotherapy  survival   Efficacy and safety of iodine-125 radioactive seeds brachytherapy for advanced non-small cell lung cancer-A meta-analysis 期刊论文 BRACHYTHERAPY, 2018, 卷号: 17, 期号: 2, 页码: 439-448 作者:  Zhang, Wenchao;  Li, Jiawei;  Li, Ran;  Zhang, Ying;  Han, Mingyong 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/11 Non-small cell lung cancer  Iodine-125  Brachytherapy  Efficacy  Meta-analysis   Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial 期刊论文 JAMA ONCOLOGY, 2018, 卷号: 4, 期号: 11, 页码: 1569-1575 作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：1/0  |  提交时间：2019/12/11 Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study 期刊论文 THORACIC CANCER, 2018, 卷号: 9, 期号: 12, 页码: 1754-1762 作者:  Zhang, Di;  Zhang, Chufeng;  Huang, Jiaqi;  Guan, Yan;  Guo, Qisen 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/11 Angiogenesis inhibitor  apatinib  advanced non-small-cell lung cancer